Evidence map›Paper›PMID 30187159›Full record

Trial reportJournal of neurology2018

Targeting phosphocreatine metabolism in relapsing-remitting multiple sclerosis: evaluation with brain MRI,

Melissa Cambron, Tatjana Reynders, Jan Debruyne, Harmen Reyngoudt, Annemie Ribbens, Erik Achten, Guy Laureys

Abstract readMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Journal of neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Annals of clinical and translational neurology · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Melissa CambronDepartment of Neurology, Universitair Ziekenhuis Brussel, Jette, Belgium. melissa.cambron@gmail.com.
Tatjana ReyndersDepartment of Neurology, Universitair Ziekenhuis Brussel, Jette, Belgium.
Jan DebruyneDepartment of Neurology, University Hospital Ghent, Ghent, Belgium.
Harmen ReyngoudtDepartment of Radiology and Nuclear Medicine, Ghent University, Ghent, Belgium.
Annemie RibbensIcometrix, Leuven, Belgium.
Erik AchtenDepartment of Radiology and Nuclear Medicine, Ghent University, Ghent, Belgium.
Guy LaureysDepartment of Neurology, University Hospital Ghent, Ghent, Belgium.
Ghent University Hospital · BEUniversitair Ziekenhuis Brussel · BEIcometrix (Belgium) · BE

Funding

MS liga vlaanderen MS steunfonds Vlaanderen
6 · The paper itself

Abstract

BACKGROUND/

objectivesFluoxetine and prucalopride might change phosphocreatine (PCr) levels via the cAMP-PKA pathway, an interesting target in the neurodegenerative mechanisms of MS.

methodsWe conducted a two-center double-blind, placebo-controlled, randomized trial including 48 relapsing-remitting MS patients. Patients were randomized to receive placebo (n = 13), fluoxetine (n = 15), or prucalopride (n = 14) for 6 weeks. Proton (

resultsNo significant changes were observed for both

conclusionBoth fluoxetine and prucalopride had a symptomatic effect on upper limb function, fatigue, and depression, but this should be interpreted with caution. No effect of treatment was found on

Indexed as

AdultBenzofuransBrainDouble-Blind MethodFemaleFluoxetineGray MatterHumansMagnetic Resonance ImagingMagnetic Resonance SpectroscopyMaleMultiple Sclerosis, Relapsing-RemittingNeuroprotective AgentsOrgan SizePhosphocreatinePhosphorus IsotopesBenzofuransFluoxetineNeuroprotective AgentsPhosphocreatinePhosphorus IsotopesProtonsprucaloprideFluoxetineMagnetic resonance spectroscopyMultiple sclerosisPhosphocreatinePrucalopride

Identifiers

PMID30187159
OpenAlexW2891644778

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.